formulation Flashcards
intranasal anatomy
2 nostrils separated by septum
nasal vestibule (hairy)
respiratory region
olfactory region
nasal vestibule
exposed to external environment, hair to keep out large particles
respiratory region
3 turbinates/ conchae (Superior, middle, inferior)
- Creates a vortex to regulate air temperature to body temp, prevent damage to lungs
- Access to CNS:
□ Ciliated columnar epithelial cells
□ Drug dissolve in mucous layer —> paracellular/ transcellular/ intraneuronal
OLFACTORY REGION
- In olfactory recess, uppermost area. Target for direct nose-brain delivery
- Direct connection to CNS
- Highly vascularised. ~15cm2 (makes up 10% of nasal SA)
- Access to CNS:
1) Transcellular
2) Paracellular
3) Intraneuronal, shuttle through neurons, not as common
Transcellular
active mechanism (absorb through cell) push it out other side, shuttle
Slow, ~13hrs
Paracellular transport
a) in interstitial space, tight junction between cells. Small molecules
b) Rapid uptake
c) High turnover of olfactory sensory neurons, leave large gaps for bigger molecules
ADV of intranasal
Non-invasive
Can self-admin
Bypass hepatic 1st pass effect
Short onset of effect, faster
criteria for nasal spray
- stability with formulated pdt
- user friendly design for pt compliance
(access olfactory region, bypass vestibular (hair) no need adjust etc) - reliability (reproducible same dose)
(specific metering, spray-producing pump mechanism, spray content uniformity, spray pattern & plume geometry)
7 Barriers intranasal CNS drug delivery — protective mechanism of nose
MuPHCEEV
- Nasal epithelial layer
- Nasal mucus (~5um)
□ Viscous layer, incr hydration in nose - Metabolic enzymes
□ Not as extensive as rest of body - Efflux pumps
- Hair
□ When mole size too large, irritate nose hair = SNEEZE - Mucociliary clearance
□ Push down into GIT, 10-15mins CL - Volume
□ Olfactory region is only 10% SA, 15cm2 limited drug conc, vol
Lipinski’s rule of 5: Characteristics of an ideal drug candidate for CNS drug delivery
for solubility & permeability
< 500 Da (<300Da for hydrophilic, <1kDa for lipo)
log P <5
unionised
=/< 5 H bond donors (H linked to e/w grp)
=/< 10 H bond acceptors (e/w)
other characteristics
○ pH 4-7.4
○ Tonicity 300-700 mOsmol
○ Volume (max 200uL)
- Metered dosing is an impt function of device
osmolality
higher osmolarity facilitates conc gradient
high conc of mucus layer where drug deposited —> area of low conc (epithelial, semi permeable mem in cerebral space)
** better to have higher osmolarity in formulation, as dilution in IN cavity. range of (300-700 mOsmol)
Rationalise strategies of drug delivery systems in targeting CNS disorders and conditions
○ Make the drug physically manageable
○ Improve drug solubility
○ Improve drug absorption, permeability
○ Protect drug candidate from degradation and excretion
○ Improve drug retention
- Prevent mucociliary action, incr duration of action
○ Reduce SE (through targeting)
- Prevent interaction with receptors in other organs
○ Incr dosing
- Reduce freq of admin – improve pt compliance
types of delivery system
drug carriers in susp
- nanoparticles
- liposomes
- polymer based, excipients
- nano/ microemulsions
powders, gels (in situ)
list of excipients
diluent
Buffer salts/ pH adjustment
Preservatives
chelators
solvent
Stabiliser/ co-solvent/ surfactant
Permeation enhancer
Viscosity modifiers
Tonicity adj
flavouring
diluent
add bulk
eg water
buffer salts, pH adjustment
Maintain pH, Integrity, stability by conjugate acid-base pair
added H+ – removed by CB
added OH- – removed by CA
eg:
acetic, citric, hcl acids (0.12/ 0.10%)
NaOH, sodium borate, sodium acetate, citrate, phosphates
